Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMLA vs ARESTOCAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Topical anesthesia of intact skin for superficial procedures,Topical anesthesia of genital mucous membranes for minor superficial procedures,Local analgesia prior to lumbar puncture (off-label),Local analgesia prior to vaccination (off-label)
Local or regional anesthesia for dental procedures,Infiltration anesthesia,Nerve block anesthesia
Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
After topical application, the terminal elimination half-life of lidocaine is approximately 1.5-2 hours; prilocaine half-life is approximately 1.5 hours. In neonates, half-life may be prolonged due to immature hepatic function. Clinical context: Steady state is achieved within 12-24 hours with repeated application.
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Lidocaine is primarily metabolized by CYP1A2 to monoethylglycinexylidide (MEGX) and further by CYP3A4; prilocaine is metabolized by amidases to o-toluidine metabolites that can oxidize hemoglobin to methemoglobin.
Primarily metabolized by the liver via hydrolysis by esterases (though it is an amide, it may be partially hydrolyzed) and conjugation. The major metabolic pathways involve CYP1A2 and CYP3A4.
Lidocaine and prilocaine are metabolized in the liver; lidocaine metabolites (primarily 4-hydroxyxylidine) and prilocaine metabolites (primarily o-toluidine) are excreted renally. Less than 5% of unchanged lidocaine and prilocaine are excreted unchanged in urine. Fecal excretion is negligible.
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Lidocaine: 65-70% bound to alpha-1-acid glycoprotein and albumin. Prilocaine: 55% bound to albumin.
Approximately 70% bound primarily to alpha-1-acid glycoprotein (AAG) and to a lesser extent albumin.
Lidocaine: Vd approximately 1.0-1.5 L/kg; prilocaine: Vd approximately 1.5-2.0 L/kg. Clinical meaning: Large Vd indicates extensive tissue distribution, including into the CNS and adipose tissue.
Volume of distribution is 0.8–1.5 L/kg, reflecting extensive tissue distribution; higher in neonates and infants.
Topical bioavailability: 20-30% for lidocaine and prilocaine when applied to intact skin under occlusion; higher (up to 80%) on mucous membranes or abraded skin. Systemic absorption is minimal with recommended doses, but can be significant with prolonged application or large surface areas.
Topical: variable, approximately 30–50% absorbed through intact skin; Oral: negligible due to extensive first-pass metabolism (bioavailability <10%); Intravenous: 100%.
No dose adjustment required for renal impairment; however, use with caution in patients with severe renal impairment due to potential accumulation of lidocaine and prilocaine metabolites.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
In Child-Pugh Class B or C, use with caution and consider reduced application area or shorter application time due to reduced metabolism of lidocaine and prilocaine; specific dose modifications not established.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Infants and children: Apply 1-2 g per 10 cm², with maximum application area based on weight: 10 cm² for infants 1-3 months, 20 cm² for 3-12 months, 100 cm² for 1-6 years, 200 cm² for 7-12 years; application time 30-60 minutes depending on age and procedure.
1-3 mg/kg intramuscularly every 60-90 minutes, max 200 mg per dose; maximum cumulative dose 400 mg/12 hours.
No specific dose adjustment; use with caution in elderly due to increased risk of systemic absorption from thinner skin and potential comorbidities; consider smaller application area or shorter duration.
Initiate at lowest effective dose (2 mg/kg) due to increased sensitivity and potential for prolonged duration; monitor for adverse effects.
EMLA cream can cause methemoglobinemia, especially in children under 12 months, patients with glucose-6-phosphate dehydrogenase deficiency, or those taking oxidizing drugs. Serious and fatal methemoglobinemia has been reported; monitor for signs and symptoms.
There is no FDA black box warning for Arestocaine hydrochloride.
Avoid application to open wounds, mucous membranes (except genital), or areas with altered skin barrier. Use with caution in patients with severely traumatized mucosa or sepsis. Monitor for methemoglobinemia, especially in young children. Do not apply to large areas or for prolonged periods. Consider risk of systemic toxicity if applied to inflamed skin or large areas.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,Risk of methemoglobinemia in patients with glucose-6-phosphate dehydrogenase deficiency
Hypersensitivity to lidocaine, prilocaine, or other amide anesthetics; known history of methemoglobinemia; application to eyes or on tympanic membrane; patients with severe hepatic disease (due to impaired metabolism).
Hypersensitivity to amide-type local anesthetics,Severe hypotension,Myasthenia gravis (relative contraindication),Bradycardia
No known food interactions. Avoid alcohol if large amounts of lidocaine/prilocaine are absorbed (rare).
No specific food interactions; avoid hot foods until numbness resolves to prevent burns.
EMLA (lidocaine 2.5% and prilocaine 2.5%) is FDA Pregnancy Category B. Lidocaine and prilocaine cross the placenta. In first trimester, no increased risk of major malformations in human data. Second and third trimesters: no known fetal harm from topical use. Methemoglobinemia risk in fetus if high doses or prolonged use, especially with prilocaine.
Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. In second and third trimesters, risk of placental transfer and fetal bradycardia; use only if clearly needed.
Lidocaine and prilocaine are excreted into breast milk in low amounts. M/P ratio: lidocaine ~0.4-0.6, prilocaine ~1.0-1.4. Infant dose ~1-2% of maternal weight-adjusted dose. Risk of methemoglobinemia in premature or G6PD-deficient infants. Use with caution.
No data on excretion in human milk. M/P ratio unknown. Caution advised; discontinue breastfeeding or drug based on importance of drug to mother.
No specific dose adjustments required for topical application. Physiologic changes in pregnancy (increased plasma volume, decreased protein binding) do not significantly alter systemic absorption from intact skin. Avoid large areas, prolonged application, or abraded skin to minimize systemic load.
Increased plasma volume and decreased plasma protein binding may require dose adjustments. However, no established guidelines; use lowest effective dose and shortest duration.
EMLA (eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) requires at least 60 minutes of occlusive application for dermal analgesia. Apply to intact skin only; avoid mucous membranes due to rapid absorption. Do not use in infants <37 weeks postconceptual age due to methemoglobinemia risk. Maximum application area: 10% body surface in infants. Onset is slower on thicker skin (e.g., back vs. antecubital). Remove cream after 4 hours to prevent systemic toxicity.
ARESTOCAINE HYDROCHLORIDE (presumed anesthetic) is not a recognized drug; likely a misspelling of articaine or similar. If referring to articaine, clinical pearls: 1) Onset within 1-3 minutes, duration 1-3 hours; 2) Metabolized by plasma esterases, caution in pseudocholinesterase deficiency; 3) Maximum dose 7 mg/kg (adults) to avoid CNS/cardiac toxicity; 4) Contains sulfites, avoid in allergic patients.
Apply a thick layer (1-2 mm) to intact skin and cover with occlusive dressing for at least 60 minutes before procedure.,Do not use on broken skin, eyes, or near mucous membranes.,Wash hands after application and avoid touching eyes.,Remove cream and dressing just before procedure; do not leave on longer than 4 hours.,Possible mild skin reactions: blanching, redness, swelling. Serious allergic reactions are rare but seek medical help if difficulty breathing or hives occur.,Inform your doctor if you have liver disease, G6PD deficiency, or are taking other numbing medicines.
Avoid chewing or biting lips/cheeks while numb to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Do not consume hot foods or beverages until sensation returns.,Inform dentist of all medications, especially MAOIs or anticoagulants.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMLA vs ARESTOCAINE HYDROCHLORIDE, answered by our medical review team.
EMLA is a Local Anesthetic that works by EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.. ARESTOCAINE HYDROCHLORIDE is a Local Anesthetic that works by Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMLA and ARESTOCAINE HYDROCHLORIDE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMLA is: Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.. The standard adult dose of ARESTOCAINE HYDROCHLORIDE is: 2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMLA and ARESTOCAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMLA is classified as Category C. EMLA (lidocaine 2.5% and prilocaine 2.5%) is FDA Pregnancy Category B. Lidocaine and prilocaine cross the placenta. In first trimester, no increased risk of major malformations in . ARESTOCAINE HYDROCHLORIDE is classified as Category C. Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.